Monoclonal antibodies in diagnosis and therapy

  title={Monoclonal antibodies in diagnosis and therapy},
  author={Thomas A. Waldmann},
  pages={1657 - 1662}
Monoclonal antibodies have been applied clinically to the diagnosis and therapy of an array of human disorders, including cancer and infectious diseases, and have been used for the modulation of immune responses. Effective therapy using unmodified monoclonal antibodies has, however, been elusive. Recently, monoclonal antibody-mediated therapy has been revolutionized by advances such as the definition of cell-surface structures on abnormal cells as targets for effective monoclonal antibody… 

Monoclonal Antibodies as Therapeutic Agents

Immunoconjugates which are comprised of monoclonal antibody linked to a chemotherapeutic agent or source(s) of radiation are discussed to treat cancer.

Advances in monoclonal antibody therapy of cancer.

This report briefly overviews recent advances in the field of monoclonal antibody therapy of cancer and provides insight regarding the promises and limitations of this novel therapeutic approach.

Monoclonal antibodies in cancer detection and therapy.

Monoclonal Antibodies in Cancer Treatment

An overview of the clinical experience with monoclonal antibodies in cancer treatment over the past 5 years is presented, highlighting the successes and advances, as well as noting limitations of antibody therapeutics.

Cytokine Receptor Directed Therapy with Genetically Engineered Monoclonal Antibodies Armed with Radionuclides

The hybridoma technique of Kohler and Milstein (1975) rekindled interest in the use of antibodies targeted to cell surface antigens to treat cancer patients. However, such monoclonal antibodies have



Bispecific antibody: a tool for diagnosis and treatment of disease

This approach has enormous potential applications for producing tailor‐made bispecific antibodies, and will enable widespread clinical uses of these antibodies both for diagnostic purposes and therapy.

Therapy with monoclonal antibodies to CD4: potential not appreciated?

  • B. Hall
  • Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1989
Investigation to determine the best monoclonal antibody to use in humans with respect to its epitope, immunoglobulin subclass, and capacity to deplete CD4+ cells is required to maximize the potential of this therapy before clinical trial.

A clinical trial of anti-idiotype therapy for B cell malignancy.

Mouse monoclonal anti-idiotype antibodies shows promise as an alternative modality for the treatment of B cell malignancy and further study will be needed to determine the mechanisms of the antitumor effect and to improve the clinical results.

Strategies in antibody therapy of cancer

This review compares the different strategies of antibody therapy, both clinical and experimental, and points out their relative merits and limitations.

Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

The Mr 55,000 interleukin 2 receptor peptide (Tac; CD25) is not expressed by normal resting T-cells but is markedly up-regulated in adult T-cell leukemia and other malignancies, as well as on T-cells

Monoclonal antibodies for treating cancer.

As a therapeutic modality, monoclonal antibodies are still promising but their general use will be delayed for several years, and new approaches using human antibodies and reducing the human antiglobulin response should facilitate treatment.

Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

It is shown that anti-idiotype antibodies can be used to monitor B-cell tumors and to investigate the biology of these tumors, and the unique immunoglobulin variable region of each lymphoma clone may be considered a tumor-specific marker.

Genetically engineered antibody molecules.

Hybrid antibodies can target sites for attack by T cells

It is shown that heteroconjugates of monoclonal antibodies (referred to hereafter as hybrid antibodies), in which one of the component binding sites is anti-T-cell receptor and the other component binding site is directed against any chosen target antigen, can focus T cells to act at the targeted site.

Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

A bispecific hybrid antibody with dual specificity for CD3 and a rat immunoglobulin light chain allotype is constructed that could mediate ECR to a range of target cells, each coated with distinct surface-binding rat monoclonal antibodies.